Ultragenyx Pharmaceutical Inc. (RARE) Social Stream
ULTRAGENYX PHARMACEUTICAL INC (RARE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering ULTRAGENYX PHARMACEUTICAL INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-05 | 16 | $185 | $73 | $146.2 | $42.98 | 240.16% |
| 2022-01-11 | 16 | $185 | $73 | $143.933 | $42.98 | 234.88% |
| 2022-01-25 | 16 | $185 | $73 | $143 | $42.98 | 232.71% |
| 2022-01-26 | 16 | $185 | $73 | $142.4 | $42.98 | 231.32% |
| 2022-01-31 | 16 | $185 | $73 | $140 | $42.98 | 225.73% |
| 2022-02-11 | 16 | $185 | $73 | $140 | $42.98 | 225.73% |
| 2022-02-14 | 15 | $185 | $73 | $139.466 | $42.98 | 224.49% |
| 2022-04-26 | 15 | $186 | $73 | $139.533 | $42.98 | 224.65% |
| 2022-04-28 | 15 | $186 | $73 | $139.666 | $42.98 | 224.96% |
| 2022-05-05 | 15 | $186 | $73 | $138.461 | $42.98 | 222.15% |
| 2022-05-09 | 13 | $186 | $71 | $129.538 | $42.98 | 201.39% |
| 2022-05-18 | 13 | $186 | $71 | $126.846 | $42.98 | 195.13% |
| 2022-05-24 | 14 | $186 | $71 | $125 | $42.98 | 190.83% |
| 2022-07-28 | 13 | $185 | $70 | $121.5 | $42.98 | 182.69% |
| 2022-08-01 | 14 | $185 | $68 | $117 | $42.98 | 172.22% |
| 2022-08-02 | 14 | $185 | $60 | $112.666 | $42.98 | 162.14% |
| 2022-08-13 | 14 | $185 | $60 | $114.5 | $42.98 | 166.4% |
| 2022-09-17 | 13 | $185 | $60 | $117.266 | $42.98 | 172.84% |
| 2022-10-12 | 11 | $185 | $60 | $117.266 | $42.98 | 172.84% |
| 2022-10-21 | 13 | $185 | $50 | $112 | $42.98 | 160.59% |
| 2022-10-25 | 13 | $185 | $50 | $111.5 | $42.98 | 159.42% |
| 2022-11-03 | 14 | $164 | $49 | $102.312 | $42.98 | 138.05% |
| 2022-11-04 | 14 | $143 | $49 | $101 | $42.98 | 134.99% |
| 2022-12-07 | 14 | $143 | $49 | $98.125 | $42.98 | 128.3% |
| 2022-12-13 | 14 | $143 | $49 | $94.937 | $42.98 | 120.89% |
| 2023-01-13 | 15 | $143 | $49 | $94.176 | $42.98 | 119.12% |
| 2023-01-26 | 15 | $143 | $48 | $94.117 | $42.98 | 118.98% |
The Trend in the Analyst Price Target
RARE's average price target has moved down $62.88 over the prior 23 months.
Over the past 51 weeks, RARE's average upside potential has been 130.3%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-04-19 | 15 | 186 | 73 | 139.533 | 78.10 | 78.66% |
| 2022-09-17 | 12 | 185 | 60 | 117.266 | 46.03 | 154.76% |
| 2022-10-13 | 13 | 185 | 50 | 112.000 | 39.65 | 182.47% |
| 2022-10-21 | 13 | 185 | 50 | 111.500 | 38.49 | 189.69% |
| 2023-01-08 | 15 | 143 | 49 | 94.176 | 46.66 | 101.83% |
RARE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.43 | 11 | 1 | 3 | 0 | 0 | 15 |
The Trend in the Broker Recommendations
Over the past 153 days, RARE's average broker recommendation rating improved by 0.32.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- RARE has a higher upside potential (average analyst target price relative to current price) than 2881.11% of stocks in the large market cap category.
- ULTRAGENYX PHARMACEUTICAL INC's number of analysts covering the stock is greater than 2759.1% of Pharmaceutical Products stocks.
- ULTRAGENYX PHARMACEUTICAL INC's average analyst price target is greater than 2723.69% of Pharmaceutical Products stocks.
- RARE has a lower variance in analysts' estimates than -2594.52% of stocks in the large market cap category.
Stocks similar to ULTRAGENYX PHARMACEUTICAL INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CTLT, TEVA, and PRGO.
View All Top Stocks by Price Target
Is RARE a Buy, Hold or Sell? See the POWR Ratings now!